Cargando…

89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析

OBJECTIVE: To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. METHODS: We collected and analyzed the clinical data of 89 patients with non-Hodgkin lymphoma-associat...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120126/
https://www.ncbi.nlm.nih.gov/pubmed/33979978
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.04.010
_version_ 1783691991345790976
collection PubMed
description OBJECTIVE: To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. METHODS: We collected and analyzed the clinical data of 89 patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis who were treated at Huadong Hospital from March 2013 to May 2020. The data were analyzed via log-rank and Cox multivariate analyses. RESULTS: The median overall survival time of the 89 cases was 10.2 months. Patients with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis did not reach the median overall survival time. The median overall survival times of T-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis were 10.2 and 3.0 months, respectively. The pathological type of non-Hodgkin lymphoma(OS: P=0041, PFS: P=0.015), ECOG score ≥3(OS: P=0.031, PFS: P=0.030), hematopoietic stem cell transplantation(OS: P=0.005, PFS: P=0.040), lymphadenopathy(OS: P=0.007, PFS: P=0.012), and splenomegaly(OS: P=0.276, PFS: P=0.324)were related to the overall survival and progression-free survival of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Splenectomy could improve the prognosis of patients with lymphoma-associated hemophagocytic lymphohistiocytosis, especially T-cell lymphomaassociated hemophagocytic lymphohistiocytosis. CONCLUSION: The clinical characteristics of patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis were similar but were different in the overall survival rate and the effect of prognostic factors. We suggested that patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis should receive more than combined chemotherapy. To improve the prognosis and survival rate of patients, those with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphomaassociated hemophagocytic lymphohistiocytosis promptly require hematopoietic stem cell transplantation. Moreover, patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis should consider splenectomy.
format Online
Article
Text
id pubmed-8120126
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-81201262021-06-08 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. METHODS: We collected and analyzed the clinical data of 89 patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis who were treated at Huadong Hospital from March 2013 to May 2020. The data were analyzed via log-rank and Cox multivariate analyses. RESULTS: The median overall survival time of the 89 cases was 10.2 months. Patients with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis did not reach the median overall survival time. The median overall survival times of T-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis were 10.2 and 3.0 months, respectively. The pathological type of non-Hodgkin lymphoma(OS: P=0041, PFS: P=0.015), ECOG score ≥3(OS: P=0.031, PFS: P=0.030), hematopoietic stem cell transplantation(OS: P=0.005, PFS: P=0.040), lymphadenopathy(OS: P=0.007, PFS: P=0.012), and splenomegaly(OS: P=0.276, PFS: P=0.324)were related to the overall survival and progression-free survival of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Splenectomy could improve the prognosis of patients with lymphoma-associated hemophagocytic lymphohistiocytosis, especially T-cell lymphomaassociated hemophagocytic lymphohistiocytosis. CONCLUSION: The clinical characteristics of patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis were similar but were different in the overall survival rate and the effect of prognostic factors. We suggested that patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis should receive more than combined chemotherapy. To improve the prognosis and survival rate of patients, those with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphomaassociated hemophagocytic lymphohistiocytosis promptly require hematopoietic stem cell transplantation. Moreover, patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis should consider splenectomy. Editorial office of Chinese Journal of Hematology 2021-04 /pmc/articles/PMC8120126/ /pubmed/33979978 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.04.010 Text en 2021年版权归中华医学会所有 https://creativecommons.org/licenses/by-nc-sa/3.0/This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title_full 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title_fullStr 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title_full_unstemmed 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title_short 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
title_sort 89例非霍奇金淋巴瘤相关噬血细胞综合征临床特点和疗效分析
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8120126/
https://www.ncbi.nlm.nih.gov/pubmed/33979978
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2021.04.010
work_keys_str_mv AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī
AT 89lìfēihuòqíjīnlínbāliúxiāngguānshìxuèxìbāozōnghézhēnglínchuángtèdiǎnhéliáoxiàofēnxī